1 / 3

Ibrutinib

Boc Sciences offers 936563-96-1 Ibrutinib in bulk, please inquire us to get a quote for 936563-96-1 Ibrutinib.<br>https://www.bocsci.com/pci-32765-ibrutinib-cas-936563-96-1-item-314184.html<br>

bocsci2018
Télécharger la présentation

Ibrutinib

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. brutinib - CAS 936563-96-1 Catalog number: B0084-314184 Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It binds to BTK to suppress both B-cell activation and B-cell-mediated signaling, and is approved for the treatment of B cell cancers, including mantle cell lymphoma, chronic lymphocytic leukemia and Waldenström's Macroglobulinemia. Please be kindly noted that our product can only be used for research to orgnizations or companies and we don't cooperate with personal buyers. Category Inhibitor Targets BTK SARS-CoV-2 Molecular Formula C25H24N6O2 Molecular Weight 440.51 Ordering Information Catalo g Numbe r Siz e Pric e Stoc k Quantity B0084- 314184 $169In 1 g stock 0 Bulk Inquiry Add to cart Chemical Information Category Inhibitor Molecular Formula

  2. C25H24N6O2 Molecular Weight 440.51 Specification Properties QC Data Reference Reading     Purity ≥95% Appearance White Solid Synonyms PCI32765; PCI-32765; PCI 32765; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrim idin-1-yl]piperidin-1-yl]prop-2-en-1-one Clinical Trial Information NCT Number Title Condition Or Disease Phase Start Date Sponsor Status NCT00849654Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma B-Cell Lymphoma Phase 1 February 2009 Pharmacyclics LLC. Completed NCT01105247Safety of PCI-32765 in Chronic Lymphocytic Leukemia B-cell Chronic Lymphocytic Leukemia Phase 2 May 2010Pharmacyclics LLC. Completed NCT01109069Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia B-cell Chronic Lymphocytic Leukemia Phase 2 June 2010 Pharmacyclics LLC. Enrolling by invitation NCT01217749Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL B-cell Chronic Lymphocytic Leukemia Phase 2 December 2010 Pharmacyclics LLC. Completed NCT01236391Safety and Efficacy of PCI- 32765 in Participants With Mantle Cell Phase 2 February Pharmacyclics Completed

  3. Relapsed/Refractory Mantle Cell Lymphoma (MCL) Lymphoma 2011 LLC. Preparing Stock Solutions ConcentrationVolumeMass 1 mg 5 mg 10 mg 1 mM 2.2701 mL 11.3507 mL 22.7015 mL 5 mM 0.4540 mL 2.2701 mL 4.5403 mL 10 mM 0.2270 mL 1.1351 mL 2.2701 mL 50 mM 0.0454 mL 0.2270 mL 0.4540 mL https://www.bocsci.com/pci-32765-ibrutinib-cas-936563-96-1-item-314184.html

More Related